VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX - Get Free Report) in a report issued on Tuesday. The firm set a "sell" rating on the stock.

Other equities research analysts have also recently issued reports about the stock. D. Boral Capital reaffirmed a "buy" rating and issued a $5.00 target price on shares of VolitionRx in a report on Tuesday, December 10th. Benchmark reaffirmed a "hold" rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Trading Up 3.3 %

Shares of VolitionRx stock traded up $0.02 on Tuesday, hitting $0.66. The stock had a trading volume of 116,315 shares, compared to its average volume of 97,779. The company's 50 day moving average price is $0.65 and its 200 day moving average price is $0.66. The stock has a market cap of $61.16 million, a price-to-earnings ratio of -1.83 and a beta of 1.20. VolitionRx has a 52-week low of $0.43 and a 52-week high of $1.23.

Insiders Place Their Bets

In other news, CEO Cameron John Reynolds purchased 139,811 shares of the firm's stock in a transaction on Monday, December 9th. The shares were bought at an average cost of $0.57 per share, with a total value of $79,692.27. Following the purchase, the chief executive officer now directly owns 2,117,404 shares of the company's stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Guy Archibald Innes acquired 174,764 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the purchase, the director now directly owns 617,085 shares of the company's stock, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 358,266 shares of company stock valued at $204,212. Corporate insiders own 12.80% of the company's stock.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC grew its stake in shares of VolitionRx Limited (NYSE:VNRX - Free Report) by 78.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,959 shares of the company's stock after acquiring an additional 20,249 shares during the quarter. Ground Swell Capital LLC's holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. Institutional investors own 8.09% of the company's stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.